Recursion Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2013-11-05

Employees: 500

Market Cap: $2.1B

Website: http://www.recursion.com

Introduction: Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Clinical Trials

Understanding the company landscape in AI-driven biopharma R&D

AI advancements are transforming drug discovery, with tools like AlphaFold2 enhancing protein-structure prediction. Biopharma firms are building AI capabilities through in-house expertise, acquisitions, and partnerships. Despite a decline in new AI-driven biotech companies, capital deployment has surged, with significant partnerships and some clinical trial successes. However, challenges in integration and competition persist, suggesting a future of increased M&A activity and a focus on unsaturated niches like RNA-based therapeutics.

nature.com

4 years ago

Tapping into the drug discovery potential of AI

Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.